Multidisciplinary team

What it is

A multidisciplinary team is a group of cancer specialists who review a patient's case together to plan care, a model widely adopted since the 1990s. In oncology, the key idea is that treatment decisions are made with input from more than one specialty rather than by a single doctor alone. This matters because cancer care often involves surgery, systemic therapy, radiation, pathology, imaging, symptom control, and rehabilitation, and the best plan may depend on balancing all of these.

An oncology MDT usually discusses diagnosis, stage, treatment options, sequencing of treatment, supportive care needs, and whether clinical trials or palliative care should be considered. In many hospitals, this happens in a formal tumour board or case conference before treatment starts and again if the disease changes or treatment is not working as expected. For patients and families, MDT care often means that several experts have reviewed the case, even if the patient meets them on different days.

A typical cancer MDT may include:

Team member	Main role
Surgical oncologist or site-specific surgeon	Advises on whether surgery is possible and when
Medical oncologist	Plans chemotherapy, targeted therapy, immunotherapy, or hormone therapy
Radiation oncologist	Assesses need for radiotherapy
Pathologist	Confirms cancer type, grade, margins, biomarkers
Radiologist / nuclear medicine specialist	Interprets scans and staging
Oncology nurse	Coordinates care, education, symptom monitoring
Palliative care specialist	Helps with pain, symptoms, goals of care
Dietitian, physiotherapist, psycho-oncology, social worker	Addresses nutrition, function, mental health, practical needs

In India, large cancer centres and many tertiary hospitals run site-specific tumour boards for breast, head and neck, lung, gastrointestinal, gynecologic, haematologic, and paediatric cancers. Access can still vary by city, hospital type, and cancer specialty.

How it works

The MDT model is designed to bring the main pieces of cancer information into one discussion. Before the meeting, the team gathers pathology reports, biopsy slides if needed, imaging, blood tests, performance status, prior treatments, and the patient's symptoms and preferences. During the meeting, specialists review the evidence and agree on a recommended plan or a shortlist of reasonable options.

Common MDT decisions include:

1. Whether the diagnosis is confirmed or needs more testing.
2. What stage the cancer is and whether scans are complete.
3. Whether treatment should start with surgery, chemotherapy, radiotherapy, or combined treatment.
4. Whether biomarker testing or genetic testing is needed.
5. Whether the patient should be referred for fertility counseling, nutrition support, rehabilitation, pain management, or palliative care.

The MDT does not replace the patient's own consultation. The final plan should still be explained to the patient in plain language, including expected benefits, risks, alternatives, costs, and timelines. Good MDT care also includes documenting the recommendation clearly and updating it if new information appears.

Evidence and uses

MDT care is widely considered standard practice in modern oncology because cancer treatment is complex and often requires coordinated decisions across specialties. Reviews of the literature show that MDT meetings can improve staging accuracy, adherence to guidelines, coordination of care, and the consistency of treatment recommendations. Some studies also suggest links with better outcomes in selected cancers, but the strength of evidence is not uniform across all tumour types.

The evidence base has limits. Many studies are observational rather than randomised, so it can be hard to prove that the MDT itself caused better survival. Hospitals with strong MDT systems may also have better staffing, imaging, pathology, and access to treatment, which can influence results. Even so, the overall direction of evidence supports MDT working as a quality-of-care approach.

Research has also shown that not all MDT meetings are equally multidisciplinary in practice. Attendance may be incomplete, discussion time may be short, and patient preferences or supportive care needs may receive less attention than scans and pathology. That means an MDT is most useful when it is structured, documented, and includes the right specialists for the specific cancer.

Situations where MDT review is especially valuable include:

Situation	Why MDT input helps
Newly diagnosed cancer	Confirms stage and first-line treatment plan
Borderline operable or locally advanced disease	Helps sequence chemotherapy, surgery, and radiation
Rare cancers	Brings together limited expertise
Relapsed or metastatic cancer	Reviews next-line options and goals of care
Complex pathology or biomarkers	Aligns pathology, imaging, and treatment choices
Major change in condition	Reassesses benefit, safety, and supportive care needs

When to see a clinician

If you have cancer or a strong suspicion of cancer, ask your treating doctor whether your case has been or will be discussed in an MDT or tumour board. This is especially important if the diagnosis is new, the cancer is rare, surgery is being considered, treatment options seem conflicting, or you are being told you need more than one type of treatment.

You should also ask for clarification if different doctors appear to be giving different plans, if biomarker testing has not been explained, or if you have major symptoms such as pain, weight loss, swallowing difficulty, breathlessness, or severe treatment side effects. These issues often need input beyond one specialty.

Useful questions include:

1. Which specialists reviewed my case?
2. What stage is my cancer, and what information was used to decide that?
3. What treatment sequence does the team recommend, and why?
4. Were supportive care, nutrition, fertility, and palliative care needs discussed?
5. Is a second MDT review needed if my scan or biopsy results change?

Limitations and open questions

An MDT can improve decision-making, but it does not guarantee the best outcome for every patient. The quality of the recommendation depends on complete records, attendance by the right specialists, enough discussion time, and clear follow-through after the meeting. Delays can happen if meetings are infrequent or if pathology and imaging are not available in time.

Another limitation is that patient values are not always fully represented in the room. A technically sound plan may still need to be adjusted for age, frailty, travel distance, family support, finances, work, or the patient's own goals. This is relevant in India, where treatment access, out-of-pocket costs, and distance from tertiary centres can strongly affect what is practical.

Evidence in humans supports MDT care as a good systems approach, but there is still uncertainty about which MDT structures produce the biggest gains. Open questions include how often meetings should occur, which cases need full discussion, how to include patient-reported concerns better, and how digital tools can improve decisions without replacing clinical judgment. For patients, the most useful point is simple: MDT care is a way to make cancer planning more coordinated, but you should still ask for the reasoning behind the final recommendation and how it fits your situation.